Latest Ratios: P/E Ratio -1.8x · EV/EBITDA 8.3x · ROE -23.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $90M | $109M | $130M | $313M | $649M | $498M | $465M | $577M | $456M | $584M | $563M |
| Enterprise Value | $269M | $288M | $285M | $464M | $704M | $560M | $569M | $731M | $547M | $650M | $596M |
| P/E Ratio → | -1.81 | — | — | 42.19 | 23.60 | 26.87 | 30.43 | 42.33 | 18.75 | 28.90 | 43.52 |
| P/S Ratio | 0.18 | 0.21 | 0.24 | 0.54 | 1.06 | 0.89 | 1.01 | 1.23 | 1.00 | 1.64 | 1.80 |
| P/B Ratio | 0.47 | 0.56 | 0.56 | 0.85 | 1.75 | 1.34 | 1.29 | 1.68 | 1.39 | 1.91 | 1.99 |
| P/FCF | — | — | — | — | 15.24 | 6.53 | 6.20 | — | — | — | 15.83 |
| P/OCF | — | — | 33.12 | — | 11.36 | 5.77 | 5.15 | 60.06 | 40.23 | 9.89 | 12.13 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.56 | 0.52 | 0.80 | 1.16 | 1.00 | 1.24 | 1.56 | 1.20 | 1.83 | 1.91 |
| EV / EBITDA | 8.29 | 8.85 | — | 10.29 | 11.22 | 9.81 | 13.30 | 16.29 | 9.44 | 14.85 | 16.17 |
| EV / EBIT | 19.57 | — | — | 20.22 | 17.33 | 18.17 | 24.34 | 27.88 | 14.02 | 24.22 | 29.02 |
| EV / FCF | — | — | — | — | 16.56 | 7.34 | 7.59 | — | — | — | 16.76 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.6% | 28.6% | 22.0% | 30.9% | 39.6% | 30.6% | 37.6% | 37.9% | 40.2% | 41.5% | 41.1% |
| Operating Margin | 2.7% | 2.7% | -18.6% | 4.0% | 6.7% | 5.5% | 5.0% | 5.6% | 8.6% | 7.5% | 6.6% |
| Net Profit Margin | -9.7% | -9.7% | -23.1% | 1.3% | 4.5% | 3.3% | 3.3% | 2.9% | 5.3% | 5.7% | 4.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -23.4% | -23.4% | -41.9% | 2.0% | 7.4% | 5.1% | 4.3% | 4.0% | 7.6% | 6.9% | 4.6% |
| ROA | -8.1% | -8.1% | -18.0% | 1.0% | 3.9% | 2.7% | 2.2% | 2.1% | 4.3% | 4.2% | 2.9% |
| ROIC | 2.7% | 2.7% | -16.8% | 3.7% | 7.1% | 5.2% | 3.6% | 4.3% | 7.4% | 5.9% | 4.8% |
| ROCE | 3.5% | 3.5% | -21.6% | 4.7% | 8.7% | 6.3% | 4.3% | 5.2% | 9.1% | 7.2% | 5.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.99 | 0.99 | 0.72 | 0.44 | 0.21 | 0.21 | 0.33 | 0.47 | 0.29 | 0.25 | 0.15 |
| Debt / EBITDA | 5.89 | 5.89 | — | 3.60 | 1.21 | 1.37 | 2.80 | 3.57 | 1.67 | 1.77 | 1.11 |
| Net Debt / Equity | — | 0.93 | 0.67 | 0.41 | 0.15 | 0.17 | 0.29 | 0.45 | 0.27 | 0.22 | 0.12 |
| Net Debt / EBITDA | 5.50 | 5.50 | — | 3.34 | 0.89 | 1.08 | 2.43 | 3.42 | 1.56 | 1.51 | 0.90 |
| Debt / FCF | — | — | — | — | 1.31 | 0.81 | 1.38 | — | — | — | 0.93 |
| Interest Coverage | -1.83 | -1.83 | -1.91 | 1.81 | 9.86 | 8.36 | 4.44 | 3.55 | 9.30 | 13.54 | 12.60 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.77 | 1.77 | 1.63 | 1.87 | 1.46 | 1.53 | 1.93 | 2.43 | 2.13 | 2.02 | 2.34 |
| Quick Ratio | 0.93 | 0.93 | 0.86 | 0.92 | 0.77 | 0.84 | 0.97 | 1.25 | 1.03 | 1.04 | 1.10 |
| Cash Ratio | 0.06 | 0.06 | 0.05 | 0.05 | 0.08 | 0.07 | 0.09 | 0.05 | 0.04 | 0.09 | 0.08 |
| Asset Turnover | — | 0.86 | 0.86 | 0.75 | 0.84 | 0.80 | 0.67 | 0.68 | 0.77 | 0.66 | 0.73 |
| Inventory Turnover | 2.09 | 2.09 | 2.38 | 1.82 | 2.00 | 2.51 | 1.75 | 1.78 | 1.70 | 1.69 | 1.52 |
| Days Sales Outstanding | — | 118.89 | 119.69 | 122.72 | 100.71 | 104.01 | 104.84 | 121.50 | 107.69 | 112.68 | 101.98 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 1.9% | 1.1% | 0.4% | 0.5% | 0.3% | 0.4% | 0.5% | 0.3% | 0.1% |
| Payout Ratio | — | — | — | 45.0% | 10.2% | 12.8% | 7.7% | 17.1% | 9.1% | 7.9% | 4.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 2.4% | 4.2% | 3.7% | 3.3% | 2.4% | 5.3% | 3.5% | 2.3% |
| FCF Yield | — | — | — | — | 6.6% | 15.3% | 16.1% | — | — | — | 6.3% |
| Buyback Yield | 0.0% | 0.0% | 1.1% | 5.6% | 5.6% | 1.5% | 0.6% | 0.6% | 1.6% | 0.1% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 3.0% | 6.7% | 6.0% | 2.0% | 0.8% | 1.0% | 2.1% | 0.4% | 0.1% |
| Shares Outstanding | — | $28M | $28M | $29M | $30M | $30M | $30M | $30M | $30M | $30M | $29M |
Regulatory EPA molecule bans
According to current market data, AVD trades at a P/S ratio of 0.15, which, when compared to the broader specialty chemical sector, suggests that investors are pricing the company as a distressed asset rather than a viable long-term participant in the agricultural inputs market.
The forward P/E of 6.92 implies that the market expects minimal earnings recovery in the near term, likely discounting the company's ability to navigate its current operational headwinds. This valuation gap relative to peers like Innospec indicates that the market is heavily penalizing the firm for its recent net losses and lack of clear growth catalysts.
Based on reported financial statements, AVD's ROIC has struggled to maintain positive territory, oscillating between -11.6% and 1.5% over the last ten quarters, which indicates a fundamental inability to generate returns that exceed the cost of capital in the current operating environment.
The persistent decay in ROIC suggests that the company's strategy of acquiring niche, off-patent molecules is failing to create sufficient economic value. Investors should monitor whether management can improve capital efficiency through better asset utilization or if the current portfolio remains structurally incapable of delivering adequate returns.
As reported in recent filings, the company's cash conversion cycle has remained elevated, peaking at 301 days in 2024Q2, which highlights significant friction in managing inventory and receivables compared to historical norms and industry standards for agricultural input providers.
The high days-inventory-outstanding, which reached 224 days in 2024Q3, suggests that AVD is struggling to clear its channel inventory, potentially due to the seasonal demand volatility inherent in its product mix. This inefficiency ties up critical liquidity and increases the risk of inventory obsolescence as regulatory landscapes shift.
According to quarterly balance sheet data, AVD's debt-to-equity ratio has climbed to 1.49 as of 2026Q1, a marked increase from 0.44 in 2023Q4, signaling that the company is increasingly relying on debt financing to bridge the gap created by persistent operational losses.
The deterioration in interest coverage, which has frequently dipped into negative territory, suggests that the company's ability to service its debt obligations is becoming increasingly precarious. This trend warrants close investigation, as it limits the firm's capacity to invest in new technologies like SIMPAS without further straining the balance sheet.
The P/E ratio is the most commonly misapplied metric for AVD, as it obscures the company's true earning power by failing to account for the significant non-cash charges and one-time operational adjustments that frequently distort the bottom line in this specific business model.
Because AVD operates in a niche segment where regulatory costs and inventory write-downs are common, the P/E ratio often provides a misleading picture of profitability. Analysts should instead focus on EV/EBITDA or normalized free cash flow to better assess the company's underlying ability to generate cash from its regulatory-protected assets.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AVD stock.
American Vanguard Corporation's current P/E ratio is -1.8x. The historical average is 24.8x.
American Vanguard Corporation's current EV/EBITDA is 8.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.4x.
American Vanguard Corporation's return on equity (ROE) is -23.4%. The historical average is 8.0%.
Based on historical data, American Vanguard Corporation is trading at a P/E of -1.8x. Compare with industry peers and growth rates for a complete picture.
American Vanguard Corporation has 28.6% gross margin and 2.7% operating margin.
American Vanguard Corporation's Debt/EBITDA ratio is 5.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.